Aurobindo Pharma's board approved the slump sale of its domestic branded generics business to its wholly-owned subsidiary, Auropharm Limited, for INR 143.21 crore.
The transaction, executed on April 6, 2026, is expected to be completed within 90-120 days, with economic benefits effective from April 1, 2026.
The deal is a related-party transaction between the holding company and its subsidiary, with no impact on consolidated financials.